Endo I. · Amatya V.J. · Kushitani K. · Nakagiri T. · Aoe K. · Takeshima Y.

Author affiliations

Department of Pathology, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: October 03, 2022
Accepted: December 12, 2022
Published online: February 01, 2023

Number of Print Pages: 11
Number of Figures: 8
Number of Tables: 1

ISSN: 1015-2008 (Print)
eISSN: 1423-0291 (Online)

For additional information: https://www.karger.com/PAT

Abstract

Introduction: Malignant mesothelioma is an aggressive cancer associated with asbestos exposure. Currently, the efficacy of therapeutics is limited in malignant mesothelioma, and developing more effective therapies is the need of the hour. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), have attracted attention as therapeutic targets. To explore potential therapeutic targets, we focused on miR-142-3p expression, which was found to be significantly downregulated in mesothelioma cell lines in our previous study. Methods: Mesothelioma cell lines and tissues were validated for expression of miR-142-3p or integrin subunit alpha-V (ITGAV). We transfected mesothelioma cell lines with miR-142-3p mimic and ITGAV siRNA and analyzed their biological functions. Results: We found that miR-142-3p was significantly downregulated in mesothelioma tissues. Transfection with miR-142-3p mimic significantly suppressed cell proliferation, migration, and invasion. Bioinformatics analysis of potential targets of miR-142-3p identified ITGAV. Membrane ITGAV expression in mesothelioma cell lines was confirmed using immunocytochemistry. ITGAV was significantly upregulated in mesothelioma tissues. Moreover, transfection of miR-142-3p mimics into mesothelioma cell lines significantly suppressed ITGAV expression, indicating that miR-142-3p targets ITGAV. Next, ITGAV siRNA transfection into mesothelioma cell lines inhibited cell proliferation, migration, and invasion. Further investigation of cell adhesion mechanisms showed that the miR-142-3p/ITGAV axis specifically affects mesothelioma cell adhesion via vitronectin in the extracellular matrix. Conclusion: This study proposed that the miR-142-3p/ITGAV axis is involved in tumor progression in malignant mesothelioma.

© 2023 S. Karger AG, Basel

References Pass HI, Vogelzang N, Hahn S, Carbone M. Malignant pleural mesothelioma. Curr Probl Cancer. 2004 May;28(3):93–174. Stayner L, Welch LS, Lemen R. The worldwide pandemic of asbestos-related diseases. Annu Rev Public Health. 2013 Jan;34:205–16. Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG, et al. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. Eur Respir Rev. 2016 Dec;25(142):472–86. Slaby O, Laga R, Sedlacek O. Therapeutic targeting of non-coding RNAs in cancer. Biochem J. 2017 Dec;474(24):4219–51. Quinn L, Finn SP, Cuffe S, Gray SG. Non-coding RNA repertoires in malignant pleural mesothelioma. Lung Cancer. 2015 Dec;90(3):417–26. Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol. 2009;4:199–227. Hill M, Tran N. miRNA interplay: mechanisms and consequences in cancer. Dis Model Mech. 2021 Apr;14(4):dmm047662. Alles J, Fehlmann T, Fischer U, Backes C, Galata V, Minet M, et al. An estimate of the total number of true human miRNAs. Nucleic Acids Res. 2019 Apr;47(7):3353–64. Amatya VJ, Mawas AS, Kushitani K, Mohi El-Din MM, Takeshima Y. Differential microRNA expression profiling of mesothelioma and expression analysis of miR-1 and miR-214 in mesothelioma. Int J Oncol. 2016 Apr;48(4):1599–607. Liang L, Fu J, Wang S, Cen H, Zhang L, Mandukhail SR, et al. MiR-142-3p enhances chemosensitivity of breast cancer cells and inhibits autophagy by targeting HMGB1. Acta Pharm Sin B. 2020 Jun;10(6):1036–46. Dong H, Song J. miR-142-3p reduces the viability of human cervical cancer cells by negatively regulating the cytoplasmic localization of HMGB1. Exp Ther Med. 2021 Mar;21(3):212. Zhang Y, Yang Y, Zhang Y, Liu Z. lncRNA ST8SIA6-AS1 facilitates proliferation and invasion in liver cancer by regulating miR-142-3p. Exp Ther Med. 2021 Dec;22(6):1348. Ren J, Li W, Pan G, Huang F, Yang J, Zhang H, et al. miR-142-3p modulates cell invasion and migration via PKM2-mediated aerobic glycolysis in colorectal cancer. Anal Cell Pathol. 2021 Jul;2021:9927720. Cooper J, Giancotti FG. Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance. Cancer Cell. 2019 Mar;35(3):347–67. Giancotti FG, Ruoslahti E. Integrin signaling. Science. 1999 Aug;285(5430):1028–32. Kechagia JZ, Ivaska J, Roca-Cusachs P. Integrins as biomechanical sensors of the microenvironment. Nat Rev Mol Cell Biol. 2019 Aug;20(8):457–73. Niu J, Li Z. The roles of integrin αvβ6 in cancer. Cancer Lett. 2017 Sep;403:128–37. Chastney MR, Conway JRW, Ivaska J. Integrin adhesion complexes. Curr Biol. 2021 May;31(10):R536–42. Bachmann M, Schäfer M, Mykuliak VV, Ripamonti M, Heiser L, Weißenbruch K, et al. Induction of ligand promiscuity of αVβ3 integrin by mechanical force. J Cell Sci. 2020 May;133(9). Ha SY, Shin J, Kim JH, Kang MS, Yoo H-Y, Kim H-H, et al. Overexpression of integrin αv correlates with poor prognosis in colorectal cancer. J Clin Pathol. 2014 Jul;67(7):576–81. Loeser H, Scholz M, Fuchs H, Essakly A, Damanakis AI, Zander T, et al. Integrin alpha V (ITGAV) expression in esophageal adenocarcinoma is associated with shortened overall-survival. Sci Rep. 2020 Oct;10(1):18411. Wang H, Chen H, Jiang Z, Lin Y, Wang X, Xiang J, et al. Integrin subunit alpha V promotes growth, migration, and invasion of gastric cancer cells. Pathol Res Pract. 2019 Sep;215(9):152531. Usami N, Fukui T, Kondo M, Taniguchi T, Yokoyama T, Mori S, et al. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci. 2006 May;97(5):387–94. Endo I, Amatya VJ, Kushitani K, Kambara T, Nakagiri T, Fujii Y, et al. Insulin-like growth factor 2 mRNA binding protein 3 promotes cell proliferation of malignant mesothelioma cells by downregulating p27Kip1. Front Oncol. 2021;11:795467. McDonald JC, McDonald AD. The epidemiology of mesothelioma in historical context. Eur Respir J. 1996 Sep;9(9):1932–42. Myojin T, Azuma K, Okumura J, Uchiyama I. Future trends of mesothelioma mortality in Japan based on a risk function. Ind Health. 2012 Mar;50(3):197–204. Janes SM, Alrifai D, Fennell DA. Perspectives on the treatment of malignant pleural mesothelioma. N Engl J Med. 2021 Sep;385(13):1207–18. Milano MT, Zhang H. Malignant pleural mesothelioma: a population-based study of survival. J Thorac Oncol. 2010 Nov;5(11):1841–8. Fujii Y, Amatya VJ, Kushitani K, Suzuki R, Kai Y, Kambara T, et al. Downregulation of lncRNA PVT1 inhibits proliferation and migration of mesothelioma cells by targeting FOXM1. Oncol Rep. 2022 Feb;47(2):27. Suzuki R, Amatya VJ, Kushitani K, Kai Y, Kambara T, Takeshima Y. miR-182 and miR-183 promote cell proliferation and invasion by targeting FOXO1 in mesothelioma. Front Oncol. 2018 Oct;8:446. Suzuki R, Amatya VJ, Kushitani K, Kai Y, Kambara T, Fujii Y, et al. Inhibition of miR-18a-3p reduces proliferation of mesothelioma cells and sensitizes them to cisplatin. Oncol Lett. 2020 Jun;19(6):4161–8. Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018 Apr;141(4):1202–7. Pahlavan Y, Mohammadi Nasr M, Dalir Abdolahinia E, Pirdel Z, Razi Soofiyani S, Siahpoush S, et al. Prominent roles of microRNA-142 in cancer. Pathol Res Pract. 2020 Nov;216(11):153220. Xiao P, Liu W-L. MiR-142-3p functions as a potential tumor suppressor directly targeting HMGB1 in non-small-cell lung carcinoma. Int J Clin Exp Pathol. 2015 Sep;8(9):10800–7. Zhu X, Ma S-P, Yang D, Liu Y, Wang Y-P, Lin T, et al. miR-142-3p suppresses cell growth by targeting CDK4 in colorectal cancer. Cell Physiol Biochem. 2018 Dec;51(4):1969–81. Xu T, He B-S, Pan B, Pan Y-Q, Sun H-L, Liu X-X, et al. MiR-142-3p functions as a tumor suppressor by targeting RAC1/PAK1 pathway in breast cancer. J Cell Physiol. 2020 May;235(5):4928–40. Börschel CS, Stejskalova A, Schäfer SD, Kiesel L, Götte M. miR-142-3p reduces the size, migration, and contractility of endometrial and endometriotic stromal cells by targeting integrin- and rho GTPase-related pathways that regulate cytoskeletal function. Biomedicines. 2020 Aug;8(8):291. Schwickert A, Weghake E, Brüggemann K, Engbers A, Brinkmann BF, Kemper B, et al. microRNA miR-142-3p inhibits breast cancer cell invasiveness by synchronous targeting of WASL, integrin alpha V, and additional cytoskeletal elements. PLoS One. 2015 Dec;10(12):e0143993. Takada Y, Ye X, Simon S. The integrins. Genome Biol. 2007;8(5):215. Felding-Habermann B, Cheresh DA. Vitronectin and its receptors. Curr Opin Cell Biol. 1993 Oct;5(5):864–8. Shen J, Zhu Y, Zhang S, Lyu S, Lyu C, Feng Z, et al. Vitronectin-activated αvβ3 and αvβ5 integrin signalling specifies haematopoietic fate in human pluripotent stem cells. Cell Prolif. 2021 Apr;54(4):e13012. Rouka E, Beltsios E, Goundaroulis D, Vavougios GD, Solenov EI, Hatzoglou C, et al. In silico transcriptomic analysis of wound-healing-associated genes in malignant pleural mesothelioma. Medicina. 2019 Jun;55(6):267. In Wu L, Amjad S, Yun H, Mani S, de Perrot M. A panel of emerging EMT genes identified in malignant mesothelioma. Sci Rep. 2022 Jan;12(1):1007. Janiszewska M, Primi MC, Izard T. Cell adhesion in cancer: beyond the migration of single cells. J Biol Chem. 2020 Feb;295(8):2495–505. Buckley CD, Rainger GE, Bradfield PF, Nash GB, Simmons DL. Cell adhesion: more than just glue (review). Mol Membr Biol. 1998 Oct;15(4):167–76. Lee BY, Timpson P, Horvath LG, Daly RJ. FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther. 2015 Feb;146:132–49. Sousa B, Pereira J, Paredes J. The crosstalk between cell adhesion and cancer metabolism. Int J Mol Sci. 2019 Apr;20(8):1933. Article / Publication Details

First-Page Preview

Received: October 03, 2022
Accepted: December 12, 2022
Published online: February 01, 2023

Number of Print Pages: 11
Number of Figures: 8
Number of Tables: 1

ISSN: 1015-2008 (Print)
eISSN: 1423-0291 (Online)

For additional information: https://www.karger.com/PAT

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.